{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:01:28Z","timestamp":1775728888954,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020875","name":"Universit\u00e9 de Versailles Saint-Quentin-en-Yvelines","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020875","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-025-03465-4","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:03:43Z","timestamp":1770962623000},"page":"1601-1621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Outcomes and Treatment Patterns in Advanced\/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients"],"prefix":"10.1007","volume":"43","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Macouillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danalyn","family":"Byng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friso","family":"Coerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandria","family":"Struebing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Inaam","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Tymejczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Quantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Bosquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"2","key":"3465_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11523-022-00868-z","volume":"17","author":"S Van Sanden","year":"2022","unstructured":"Van Sanden S, et al. Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in Europe: a pragmatic literature review and meta-analysis. Target Oncol. 2022;17(2):153\u201366.","journal-title":"Target Oncol"},{"issue":"3","key":"3465_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169\u201381.","journal-title":"Nat Rev Cancer"},{"key":"3465_CR3","doi-asserted-by":"publisher","first-page":"175883592412364","DOI":"10.1177\/17588359241236451","volume":"16","author":"J-B Auliac","year":"2024","unstructured":"Auliac J-B, et al. Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). Ther Adv Med Oncol. 2024;16:17588359241236452.","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"3465_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1358\/dot.2016.52.10.2541343","volume":"52","author":"CE McCoach","year":"2016","unstructured":"McCoach CE, Jimeno A. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. Drugs Today (Barc). 2016;52(10):561\u20138.","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"3465_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"key":"3465_CR6","unstructured":"European Medicines Agency: Tagrisso. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tagrisso#overview. Accessed 3 Jan 2025."},{"key":"3465_CR7","unstructured":"ESMO Clinical Practice Guidelines: Lung and Chest Tumours. https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/esmo-clinical-practice-guidelines-lung-and-chest-tumours. Accessed 3 Jan 2025."},{"issue":"5","key":"3465_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","volume":"33","author":"A Passaro","year":"2022","unstructured":"Passaro A, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33(5):466\u201387.","journal-title":"Ann Oncol"},{"issue":"21","key":"3465_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"issue":"4","key":"3465_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro A, et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377\u201391.","journal-title":"Nat Cancer"},{"issue":"1","key":"3465_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77\u201390.","journal-title":"Ann Oncol"},{"issue":"4","key":"3465_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357.","journal-title":"Ann Oncol"},{"key":"3465_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142589","author":"I Attili","year":"2024","unstructured":"Attili I, et al. Post-progression analysis of EGFR-mutant NSCLC following osimertinib therapy in real-world settings. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16142589.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3465_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","volume":"16","author":"JC Soria","year":"2015","unstructured":"Soria JC, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990\u20138.","journal-title":"Lancet Oncol"},{"key":"3465_CR15","unstructured":"Martin, C., Press Release: COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC. https:\/\/www.iaslc.org\/iaslc-news\/press-release\/compel-study-shows-continuing-osimertinib-treatment-through-progression. Accessed 24 Oct 2025. IASLC News, 2025."},{"issue":"suppl_2","key":"3465_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/annonc\/annonc1623","volume":"35","author":"S Popat","year":"2024","unstructured":"Popat S, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: second interim overall survival from MARIPOSA-2. Ann Oncol. 2024;35(suppl_2):1\u201372. https:\/\/doi.org\/10.1016\/annonc\/annonc1623.","journal-title":"Ann Oncol"},{"issue":"3","key":"3465_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40487-024-00292-5","volume":"12","author":"E Marrett","year":"2024","unstructured":"Marrett E, et al. Treatment patterns and resource use after osimertinib discontinuation in patients with EGFR + metastatic NSCLC. Oncol Ther. 2024;12(3):549\u201363.","journal-title":"Oncol Ther"},{"issue":"8","key":"3465_CR18","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1007\/s12325-024-02936-4","volume":"41","author":"J Patel","year":"2024","unstructured":"Patel J, et al. Real-world treatment patterns and clinical outcomes among patients with metastatic or unresectable EGFR-mutated non-small cell lung cancer previously treated with osimertinib and platinum-based chemotherapy. Adv Ther. 2024;41(8):3299\u2013315.","journal-title":"Adv Ther"},{"issue":"7","key":"3465_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"Fang W, et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024;332(7):561\u201370.","journal-title":"JAMA"},{"key":"3465_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.002","author":"MJ Ahn","year":"2025","unstructured":"Ahn MJ, et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol. 2025. https:\/\/doi.org\/10.1016\/j.jtho.2025.06.002.","journal-title":"J Thorac Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03465-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:13:49Z","timestamp":1775726029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03465-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3465"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03465-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors Pauline Macouillard, Sarah Park, Didier Debievre, Xavier Quantin, and Lise Bosquet have no conflicts to disclose. Authors Danalyn Byng, Jie Meng, Friso Coerts, Shannon Hunter, Yan Xiong, M. Inaam Haq, Olga Tymejczyk are employees of Daiichi Sankyo. Jie Meng, Alessandria Struebing, and Yan Xiong also report holding stock for Daiichi Sankyo. Christos Chouaid has received research grants, travel, and honoraria from AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen, Viatris, Chugai, and Amgen. Clarisse Audigier-Valette has served in a consulting or advisory role for Roche, Janssen Oncology, Lilly, BMS GmbH and Co. KG, MSD Oncology, AstraZeneca, Pfizer, Sanofi, Takeda, and Abbvie. Maurice P\u00e9rol has been a consultant for Roche, Eli Lilly, Pfizer, Boehringer Ingelheim, Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, AstraZeneca, Takeda, Gritstone, Sanofi, GlaxoSmithKline, Amgen, Abbvie, Janssen, Ipsen, Pierre Fabre, Esai, AnHeart Therapeutics, Nuvation Bio, Daiichi-Sankyo, Revolution Medicine, Regeneron, and Novocure; received grants from Roche, AstraZeneca, Takeda, and Boehringer Ingelheim; received lecture fees from Eli Lilly, Roche, AstraZeneca, Pfizer, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Takeda, Merck Sharp & Dohme, Chugai, and Illumina; and travel support from Roche, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Takeda, Amgen, and Janssen. Nicolas Girard has received research grants\/support from Abbvie, Amgen, AstraZeneca,\u00a0BeOne, Boehringer Ingelheim, Bayer, BioNTEch,\u00a0Bristol Myers Squibb, Daiichi-Sankyo, Gilead, J&J, Lilly, Sivan, and Tahio; consulted for Abbvie, Accord, Amgen, AstraZeneca,\u00a0BeOne, Bristol Myers Squibb, Daiichi-Sankyo, Ipsen, J&J, Lilly, Merck Sharp & Dohme,\u00a0Natera,\u00a0Pfizer, Pharmamar,\u00a0Pierre Fabre,\u00a0Regeneron, and Summit; served as speaker for Abbvie, Amgen, AstraZeneca,\u00a0BeOne,\u00a0Bristol Myers Squibb, Daiichi-Sankyo, J&J, Merck Sharp & Dohme; hospitality from Bristol Myers Squibb, J&J, Pierre-Fabre;\u00a0and reports employment of a family member with AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"In accordance with the authorizations issued by the French authorities for the database, no formal informed consent is required. All patients were informed about the ESME program and have approved the use of their data. The authors confirm they have permission to access and use the ESME database for this study. The authors also confirm that no form of IRB approval was required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}